Unveiling the Potential of Repurposing FDA-Approved Drugs in Pancreatic Cancer

Matthias Ilmer and Bernhard W. Renz*
Department of General, Visceral, and Transplantation Surgery, Hospital of the Ludwig-Maximilians-University (LMU), Munich 81377, Germany

Editorial
Therapeutic options for pancreatic ductal adenocarcinoma (PDAC) and, in particular, for unresectable cases are still limited. Hence, overall survival rates remain low and estimates suggest that PDAC will move up the ladder to become the number two in cancer-related deaths over the next decades [1,2]. Various factors endow PDAC with this drug resistance; one of the main contributors is the cancer niche which acts as an unsurmountable fortress due to its desmopoietic and poorly vascularized nature [3] as well as the additional activation of cancer stem cell (CSC) pathways in PDAC cells [4]. Hence, alternative treatment choices are profoundly necessary and need to be evaluated. Renz and colleagues discussed FDA-approved drugs on their theoretical antineoplastic potential in their recent comprehensive review ‘Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)’ [5].

The article is subdivided into two parts with a focus on metabolic modulators and CSC pathway inhibition. Cancer cells are chameleons in that they are very versatile and adjust easily to tough circumstances such as reduced nutrient supply within the microenvironment. Malignant transformation per se has been linked to altered metabolic pathways such as the revived concept of the Warburg effect, a kind of lactic acid fermentation in the cytosol following high rates of glycolysis instead of oxidation processes commonly found in most non-malignant cells [6]. Pancreatic CSCs seem to rely on yet another method of energy acquisition in the form of mitochondrial oxidative phosphorylation (OXPHOS) [7]. Last, another underappreciated aspect of self-sufficient metabolite production is the autolytic recycling and reusing of cell organelles by disassembling non- or dysfunctional cytoplasmic components, a process now widely known as (macro-)autophagy [8]. PDAC seems to rely heavily on this process, because comparisons to other neoplasms showed much higher levels without inducing actual cell death.

These novel insights provide opportunities to target altered metabolic pathways, especially because many FDA-approved drugs already affect many of those areas. For instance, antibiotics were shown to constrain both mitochondrial protein translation (MPT) and cancer stemness in liquid tumors [9], OXPHOS dependence might be exploitable by the combination of metformin and the BRD4 inhibitor JQ-1 in pancreatic CSCs [7], and the concept of autophagy inhibition by using chloroquine is already being evaluated in clinical phase I studies. Recent evidence suggests that cancer stemness is not a defined state, but depends on CSC pathway activity [10] and these signals can be modulated by secreted cues of the cancer microenvironment. Moreover, FDA-approved drugs have been shown to influence certain signaling cascades, which led to an inhibitory effect on cancer growth in general. Among others, components of antibiotic medications proved to possess above-mentioned properties; however, other medical drugs, such as the NK1-R blocker aprepitant, normally applied for chemotherapy-induced nausea and vomiting (CINV), revealed potent antineoplastic behavior in colorectal, hepatic and other cancer types [11,12].

One pivotal point in PDAC is the microenvironment as described before. Multiple cell types form part of the immediate surrounding and essential functions has been ascribed to pancreatic stellate cells (PSCs), a myriad of immune cells, and neural cells. The latter ones might even be involved in a positive forward feedback loop: Here, catecholamines stimulate epithelial proliferation, upregulate neurotrophin expression, thereby inducing sympathetic innervation, which causes local norepinephrine accumulation within the tumor microenvironment. This mechanism seems to be susceptible to beta-blocker treatment [13].

In the recently published review ‘Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)’, we summarize and discuss in detail the current knowledge about FDA-approved compounds with a strong potential to influence the differentiated PDAC as well its subgroup of pancreatic CSC. The list of drugs makes no claim to be complete; however, this armamentarium of substances shows we might already hold a huge medical array with potential capacity, little side effects, and high promise. Further future clinical studies will be necessary to clarify the usefulness of the mostly basic and translational scientific knowledge about those compounds.

References
1. Rahib L, Smith BD, Azenberg R, Rosenzweig AB, Fleshman JM, et al. (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74: 2913-2921.
2. Quante AS, Ming C, Rottmann M, Engel J, Boeck S, et al. (2016) Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med 5: 2649-2656.
3. Olsen P, Hanahan D (2009) Breaching the cancer fortress. Science 324: 1400-1401.
4. Ilmer M, Horst D (2015) Pancreatic CSCs and microenvironment. Genes Cancer 365-366.
5. Renz BD, Haese J, Werner J, Westphalen C, Ilmer M (2017) Repurposing established compounds to target pancreatic cancer stem cells (CSCs). Med Sci 5: 14.
6. Warburg O, Posener K, Negelein E (1924) Uber den stoffwechsel der tumoren. Biochemische Zeitschrift 152: 319-344.
7. Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, et al. (2015) MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Cell Metab 22: 590-605.

*Corresponding author: Bernhard W. Renz, Department of General, Visceral, and Transplantation Surgery, Hospital of the Ludwig-Maximilians-University (LMU), Marchioninistr. 15, 81377, Munich, Germany. Tel: +49 89 440073961; E-mail: bernhard.renz@med.uni-muenchen.de

Received December 26, 2017; Accepted December 28, 2017; Published December 30, 2017

Citation: Ilmer M, Renz BW (2018) Unveiling the Potential of Repurposing FDA-Approved Drugs in Pancreatic Cancer. J Mol Biomark Diagn 9: e128. doi: 10.4172/2155-9929.1000e128

Copyright: © 2018 Ilmer M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
8. Fujii S, Mitsunaga S, Yamazaki M, Hasebe T, Ishii G, et al. (2008) Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Science 99: 1813-1819.

9. Skrtić M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, et al. (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20: 674-688.

10. Ilmer M, Boiles AR, Regel I, Yokoi K, Michalski CW, et al. (2015) RSPO2 enhances canonical Wnt signaling to confer stemness-associated traits to susceptible pancreatic cancer cells. Cancer Res 75: 1883-1896.

11. Berger M, Neth O, Ilmer M, Garnier A, Salinas-Martin MV, et al. (2014) Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. J Hepatol 60: 985-994.

12. Ilmer M, Garnier A, Vykoukal J, Alt E, Von Schweinitz D, et al. (2015) Targeting the neurokinin-1 receptor compromises canonical Wnt signaling in hepatoblastoma. Mol Cancer Ther 14: 2712-2721.

13. Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, et al. (2017) β2 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell.